X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs DIVIS LABORATORIES - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA DIVIS LABORATORIES ABBOTT INDIA/
DIVIS LABORATORIES
 
P/E (TTM) x 41.6 31.3 133.0% View Chart
P/BV x 10.4 5.4 191.7% View Chart
Dividend Yield % 0.6 0.9 70.7%  

Financials

 ABBOTT INDIA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
DIVIS LABORATORIES
Mar-17
ABBOTT INDIA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6,0151,222 492.2%   
Low Rs3,707784 472.8%   
Sales per share (Unadj.) Rs1,236.9153.1 807.9%  
Earnings per share (Unadj.) Rs122.239.9 305.9%  
Cash flow per share (Unadj.) Rs129.044.6 289.2%  
Dividends per share (Unadj.) Rs35.0010.00 350.0%  
Dividend yield (eoy) %0.71.0 72.2%  
Book value per share (Unadj.) Rs521.2201.8 258.3%  
Shares outstanding (eoy) m21.25265.47 8.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.96.6 60.0%   
Avg P/E ratio x39.825.1 158.4%  
P/CF ratio (eoy) x37.722.5 167.6%  
Price / Book Value ratio x9.35.0 187.6%  
Dividend payout %28.625.0 114.4%   
Avg Mkt Cap Rs m103,296266,266 38.8%   
No. of employees `0003.09.7 30.4%   
Total wages/salary Rs m3,3704,687 71.9%   
Avg. sales/employee Rs Th8,891.84,175.0 213.0%   
Avg. wages/employee Rs Th1,140.0481.5 236.8%   
Avg. net profit/employee Rs Th878.31,089.3 80.6%   
INCOME DATA
Net Sales Rs m26,28440,643 64.7%  
Other income Rs m504749 67.4%   
Total revenues Rs m26,78941,392 64.7%   
Gross profit Rs m3,66514,460 25.3%  
Depreciation Rs m1441,233 11.7%   
Interest Rs m823 35.8%   
Profit before tax Rs m4,01713,953 28.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4213,349 42.4%   
Profit after tax Rs m2,59610,604 24.5%  
Gross profit margin %13.935.6 39.2%  
Effective tax rate %35.424.0 147.4%   
Net profit margin %9.926.1 37.9%  
BALANCE SHEET DATA
Current assets Rs m14,44640,105 36.0%   
Current liabilities Rs m4,7256,595 71.6%   
Net working cap to sales %37.082.5 44.9%  
Current ratio x3.16.1 50.3%  
Inventory Days Days51119 43.4%  
Debtors Days Days2081 24.2%  
Net fixed assets Rs m1,11319,995 5.6%   
Share capital Rs m213531 40.0%   
"Free" reserves Rs m10,80853,043 20.4%   
Net worth Rs m11,07653,574 20.7%   
Long term debt Rs m00-   
Total assets Rs m16,24161,585 26.4%  
Interest coverage x497.0618.4 80.4%   
Debt to equity ratio x00-  
Sales to assets ratio x1.60.7 245.2%   
Return on assets %16.017.3 92.9%  
Return on equity %23.419.8 118.4%  
Return on capital %36.326.1 139.3%  
Exports to sales %0.60-   
Imports to sales %12.625.2 50.1%   
Exports (fob) Rs m162NA-   
Imports (cif) Rs m3,32210,259 32.4%   
Fx inflow Rs m26835,384 0.8%   
Fx outflow Rs m3,92710,399 37.8%   
Net fx Rs m-3,65924,985 -14.6%   
CASH FLOW
From Operations Rs m2,51411,493 21.9%  
From Investments Rs m-800-11,372 7.0%  
From Financial Activity Rs m-803-93 862.4%  
Net Cashflow Rs m91228 3,210.9%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 11.8 66.9%  
FIIs % 0.1 19.0 0.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 17.2 99.4%  
Shareholders   18,270 31,796 57.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   ORCHID PHARMA LTD  CIPLA  ASTRAZENECA PHARMA  VENUS REMEDIES  STERLING BIOTECH  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jan 16, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - AUROBINDO PHARMA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS